Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced that the FDA has approved Selarsdi (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older
Teva Women�s Health, Inc., a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd, has announced that the FDA has accepted for...
Exelixis, Inc. announced that it has entered into a Settlement and License Agreement (Agreement) with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. This settlement resolves patent litigation brought by Exelixis in response to Teva’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Cabometyx (cabozantinib) tablets prior to the expiration of the applicable patents
Teva Pharmaceutical Industries Ltd. announced that it has signed a definitive agreement with Allergan plc to acquire Allergan Generics in...
Teva Pharmaceutical Industries announced that it has withdrawn its cash and stock proposal to acquire all of the outstanding ordinary...
Teva Pharmaceutical Industries Ltd. announced that the FDA has on 28 March 2013, approved Quartette, (levonorgestrel/ethinyl estradiol and ethinyl estradiol)...
Teva Pharmaceutical Industries announced that it has successfully completed the acquisition of Representaciones e Investigaciones M�dicas, S.A. de C.V. (Rimsa),...
Teva Pharmaceutical Industries Ltd. has announced the results of its strategic review of core therapeutic areas for the Company. The...
Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. and Alvotech announced that they have agreed to expand their existing strategic partnership agreement
Impax Laboratories, Inc. a specialty pharmaceutical company, announced that it has signed definitive agreements with Teva Pharmaceutical Industries Ltd. and...